Related Experiment Video
Updated: Jun 7, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Deconstructing cancer in 3D: models, mechanisms, and personalized solutions
Zhao Huang1, Xirui Duan2, Jun Ji3
1West China Institute of Preventive and Medical Integration for Major Diseases, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China.
Abstract:
Three-dimensional (3D) cancer models, notably patient-derived organoids (PDOs), address the critical limitations of traditional preclinical systems, including two-dimensional (2D) monolayer cultures and patient-derived xenografts (PDXs), by better recapitulating physiological tumor architecture and patient-specific heterogeneity, thereby revolutionizing oncology research. We chart the complementary technological landscape, from high-fidelity PDOs and scalable spheroids to engineered systems that reconstruct the tumor microenvironment (TME) via co-culture, organ-on-a-chip, and 3D bioprinting. Beyond foundational biology, these tools are driving functional precision medicine, where PDO avatars predict clinical drug response, and accelerating drug discovery through physiologically relevant screening. A core focus is their unparalleled utility in modeling therapy resistance, enabling the induction and multi-omic dissection of resistant clones, deconstructing stroma-mediated protection, and testing rational combination therapies to overcome relapse. Despite challenges in standardization and complete TME integration, the convergence of 3D models with single-cell omics, CRISPR screening, and artificial intelligence heralds a new era of predictive oncology. Ultimately, rigorous validation and clinical translation of these models promise to bridge the gap between bench and bedside, enabling truly personalized and effective cancer therapies.
Insights
Three-dimensional (3D) cancer models like patient-derived organoids (PDOs) offer superior recapitulation of tumor complexity compared to traditional methods. These advanced models are revolutionizing precision medicine and drug discovery by better predicting treatment response and modeling therapy resistance.
Area of Science:
- Oncology
- Biotechnology
- Translational Medicine
Background:
- Traditional 2D cancer models and patient-derived xenografts (PDXs) have limitations in mimicking tumor physiology and patient heterogeneity.
- Three-dimensional (3D) cancer models, including patient-derived organoids (PDOs), offer enhanced recapitulation of tumor architecture and patient-specific characteristics.
- These advanced models are crucial for overcoming the limitations of conventional preclinical systems in oncology research.
Purpose of the Study:
- To review the technological landscape of 3D cancer models and their applications in oncology.
- To highlight the role of 3D models in advancing functional precision medicine and drug discovery.
- To emphasize the utility of 3D models in understanding and overcoming cancer therapy resistance.
Main Methods:
- Exploration of various 3D cancer modeling technologies, including PDOs, spheroids, organ-on-a-chip, and 3D bioprinting.
- Integration of 3D models with advanced techniques such as single-cell omics, CRISPR screening, and artificial intelligence.
- Application of 3D models for predicting clinical drug response and modeling therapy resistance mechanisms.
Main Results:
- 3D cancer models, particularly PDOs, significantly improve the recapitulation of tumor microenvironment (TME) and patient heterogeneity.
- PDO avatars demonstrate utility in predicting clinical drug response, advancing functional precision medicine.
- These models enable the induction, dissection, and therapeutic targeting of therapy-resistant cancer clones.
Conclusions:
- 3D cancer models represent a significant advancement over traditional preclinical systems, offering higher physiological relevance.
- The integration of 3D models with omics and AI technologies is ushering in a new era of predictive oncology.
- Further validation and clinical translation of 3D models are essential for developing truly personalized and effective cancer therapies.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...

